Venous thromboembolism: A clinical review

Olusegun Osinbowale, Lobna Ali, Yung-wei Chi

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism, represents a signifi cant source of morbidity and mortality. It is readily diagnosed with noninvasive modalities when there is a clinical suspicion. Most patients presenting with signs and symptoms of DVT have well-known risk factors, such as a history of VTE, malignancy, recent illness, or immobilization. A subset of individuals with idiopathic VTE have no readily identifi - able risk factors. Therapeutic anticoagulation is the cornerstone of management in all patients with VTE. Adjunctive measures, such as thrombolysis and the use of vena cava fi lters, are indicated in select cases. The ideal duration of anticoagulation is unknown, but is often maintained long-term in patients with acquired or inherited thrombophilia. Warfarin is the only oral anticoagulant approved by the US Food and Drug Administration. Warfarin carries a substantial annual risk of bleeding complications, requires ongoing monitoring, and has extensive drug-drug interactions, which are causes for concern in patients requiring long-term anticoagulation. Alternative oral anticoagulants, such as direct thrombin inhibitors and factor Xa inhibitors, are subjects of active research in alternative agents for oral anticoagulation, and have been recently approved for prophylaxis in Canada and the European Union.

Original languageEnglish (US)
Pages (from-to)54-65
Number of pages12
JournalPostgraduate Medicine
Volume122
Issue number2
DOIs
StatePublished - Mar 2010
Externally publishedYes

Fingerprint

Venous Thromboembolism
Anticoagulants
Warfarin
Venous Thrombosis
Venae Cavae
Thrombophilia
Antithrombins
European Union
United States Food and Drug Administration
Pulmonary Embolism
Drug Interactions
Immobilization
Signs and Symptoms
Canada
Hemorrhage
Morbidity
Mortality
Research
Pharmaceutical Preparations
Neoplasms

Keywords

  • Anticoagulation
  • Deep vein thrombosis
  • Heparin
  • Low-molecular-weight heparin
  • Pulmonary embolism
  • Venous thromboembolism
  • Warfarin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Venous thromboembolism : A clinical review. / Osinbowale, Olusegun; Ali, Lobna; Chi, Yung-wei.

In: Postgraduate Medicine, Vol. 122, No. 2, 03.2010, p. 54-65.

Research output: Contribution to journalArticle

Osinbowale, Olusegun ; Ali, Lobna ; Chi, Yung-wei. / Venous thromboembolism : A clinical review. In: Postgraduate Medicine. 2010 ; Vol. 122, No. 2. pp. 54-65.
@article{9b28b30918cc4dd1aaf7ef6e67301e91,
title = "Venous thromboembolism: A clinical review",
abstract = "Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism, represents a signifi cant source of morbidity and mortality. It is readily diagnosed with noninvasive modalities when there is a clinical suspicion. Most patients presenting with signs and symptoms of DVT have well-known risk factors, such as a history of VTE, malignancy, recent illness, or immobilization. A subset of individuals with idiopathic VTE have no readily identifi - able risk factors. Therapeutic anticoagulation is the cornerstone of management in all patients with VTE. Adjunctive measures, such as thrombolysis and the use of vena cava fi lters, are indicated in select cases. The ideal duration of anticoagulation is unknown, but is often maintained long-term in patients with acquired or inherited thrombophilia. Warfarin is the only oral anticoagulant approved by the US Food and Drug Administration. Warfarin carries a substantial annual risk of bleeding complications, requires ongoing monitoring, and has extensive drug-drug interactions, which are causes for concern in patients requiring long-term anticoagulation. Alternative oral anticoagulants, such as direct thrombin inhibitors and factor Xa inhibitors, are subjects of active research in alternative agents for oral anticoagulation, and have been recently approved for prophylaxis in Canada and the European Union.",
keywords = "Anticoagulation, Deep vein thrombosis, Heparin, Low-molecular-weight heparin, Pulmonary embolism, Venous thromboembolism, Warfarin",
author = "Olusegun Osinbowale and Lobna Ali and Yung-wei Chi",
year = "2010",
month = "3",
doi = "10.3810/pgm.2010.03.2122",
language = "English (US)",
volume = "122",
pages = "54--65",
journal = "Postgraduate Medicine",
issn = "0032-5481",
publisher = "Medquest Communications LLC",
number = "2",

}

TY - JOUR

T1 - Venous thromboembolism

T2 - A clinical review

AU - Osinbowale, Olusegun

AU - Ali, Lobna

AU - Chi, Yung-wei

PY - 2010/3

Y1 - 2010/3

N2 - Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism, represents a signifi cant source of morbidity and mortality. It is readily diagnosed with noninvasive modalities when there is a clinical suspicion. Most patients presenting with signs and symptoms of DVT have well-known risk factors, such as a history of VTE, malignancy, recent illness, or immobilization. A subset of individuals with idiopathic VTE have no readily identifi - able risk factors. Therapeutic anticoagulation is the cornerstone of management in all patients with VTE. Adjunctive measures, such as thrombolysis and the use of vena cava fi lters, are indicated in select cases. The ideal duration of anticoagulation is unknown, but is often maintained long-term in patients with acquired or inherited thrombophilia. Warfarin is the only oral anticoagulant approved by the US Food and Drug Administration. Warfarin carries a substantial annual risk of bleeding complications, requires ongoing monitoring, and has extensive drug-drug interactions, which are causes for concern in patients requiring long-term anticoagulation. Alternative oral anticoagulants, such as direct thrombin inhibitors and factor Xa inhibitors, are subjects of active research in alternative agents for oral anticoagulation, and have been recently approved for prophylaxis in Canada and the European Union.

AB - Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism, represents a signifi cant source of morbidity and mortality. It is readily diagnosed with noninvasive modalities when there is a clinical suspicion. Most patients presenting with signs and symptoms of DVT have well-known risk factors, such as a history of VTE, malignancy, recent illness, or immobilization. A subset of individuals with idiopathic VTE have no readily identifi - able risk factors. Therapeutic anticoagulation is the cornerstone of management in all patients with VTE. Adjunctive measures, such as thrombolysis and the use of vena cava fi lters, are indicated in select cases. The ideal duration of anticoagulation is unknown, but is often maintained long-term in patients with acquired or inherited thrombophilia. Warfarin is the only oral anticoagulant approved by the US Food and Drug Administration. Warfarin carries a substantial annual risk of bleeding complications, requires ongoing monitoring, and has extensive drug-drug interactions, which are causes for concern in patients requiring long-term anticoagulation. Alternative oral anticoagulants, such as direct thrombin inhibitors and factor Xa inhibitors, are subjects of active research in alternative agents for oral anticoagulation, and have been recently approved for prophylaxis in Canada and the European Union.

KW - Anticoagulation

KW - Deep vein thrombosis

KW - Heparin

KW - Low-molecular-weight heparin

KW - Pulmonary embolism

KW - Venous thromboembolism

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=77950348481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950348481&partnerID=8YFLogxK

U2 - 10.3810/pgm.2010.03.2122

DO - 10.3810/pgm.2010.03.2122

M3 - Article

C2 - 20203456

AN - SCOPUS:77950348481

VL - 122

SP - 54

EP - 65

JO - Postgraduate Medicine

JF - Postgraduate Medicine

SN - 0032-5481

IS - 2

ER -